-
摘要: [目的]探究西妥昔单抗联合氟尿嘧啶、伊立替康治疗HER2阳性胃癌的临床疗效。[方法]选取我院2011年1月~2013年1月HER2阳性晚期胃癌42例,分为西妥昔单抗组和化疗组,化疗组患者使用氟尿嘧啶、伊立替康治疗,西妥昔单抗组在化疗组的基础上联合西妥昔单抗。治疗4个疗程后,评价2组的治疗有效率、疾病控制率、不良反应。随访2年,统计2组的生存率和生存期。[结果]西妥昔单抗组治疗有效率和疾病控制率均较化疗组高,分别为52.2%[BFZ]:[BF]36.8%,78.3%[BFZ]:[BF]57.9%,差异有统计学意义(P＜0.05)。西妥昔单抗组与化疗组比较安全性相对较好,但是生存期差异无统计学意义。生存率西妥昔单抗组较高(78.3%)。[结论]化疗药物的基础上联合靶向药物治疗晚期胃癌具有一定的临床推广价值。
-
-
[1] MOEHLER M, MUELLER A, TRARBACH T, et al.Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer:a prospective multi-center biomarker-oriented phase II study[J].Ann Oncol, 2011, 22:1358-1366.
[2] 谭景浪.胃癌相关基因Her 2的研究新进展[J].当代医学, 2014, 20(3):14-15.
[3] 王李杰, 白莉, 焦顺昌.胃癌靶向治疗的研究进展[J].世界华人消化杂志, 21(24):2385-2396
[4] WöLL E, GREIL R, EISTERER W, et al.Oxaliplatin, irinote-can and cetuximab in advanced gastric cancer.A multicenter phase II trial(Gastric-2)of the Arbe-itsgemeinschaft Medikamentose Tumortherapie(AGMT)[J].Anticancer Res, 2011, 31:4439-4443.
[5] BANG Y J, VANCUTSEM E, FEYEREISLOVA A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3, open-label, randomised controlled trial[J].Lancet, 2010, 376:687-697.
[6] VAN CUTSEM E, YEH K-H, BANG Y-J, et al.Phase III trial of everolimus in previously treated patients with advanced gastric cancer:GRANITE-1[J].J Clin Oncol, 2012, 30:abstr LBA3.
[7] GSCHWIND A, FISCHER O M, ULLRICH A.The discovery of receptor tyrosine kinases:targets for cancer therapy[J].Nat Rev Cancer, 2004, 4:361-370.
[8] SIRICA A E.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma[J].World J Gastroenterol, 2008, 14:7033-7058.
[9] 林绵辉, 吴芳, 邓小戈, 等.曲妥珠单抗治疗HER2阳性早期乳腺癌患者预后的Meta分析[J].循证医学, 2006, 6(6):352-356.
-
计量
- 文章访问数: 128
- PDF下载数: 171
- 施引文献: 0
下载: